{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:20:22Z","timestamp":1794550822571,"version":"4.9.1"},"reference-count":158,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/17425247.2022.2105318","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T08:11:46Z","timestamp":1658995906000},"page":"927-944","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":85,"title":["Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules"],"prefix":"10.1080","volume":"19","author":[{"given":"Andrea","family":"Gonella","sequence":"first","affiliation":[{"name":"MedinCell S.A","place":["Jacou, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvestre","family":"Grizot","sequence":"additional","affiliation":[{"name":"MedinCell S.A","place":["Jacou, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"MedinCell S.A","place":["Jacou, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"L\u00f3pez Noriega","sequence":"additional","affiliation":[{"name":"MedinCell S.A","place":["Jacou, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Richard","sequence":"additional","affiliation":[{"name":"MedinCell S.A","place":["Jacou, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9970.1"},{"key":"e_1_3_4_4_1","unstructured":"What Are \u201cBiologics\u201d Questions and Answers | FDA [Internet]. cited 2021 Sep 9. Available from: https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.183"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.02.019"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00904-4"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"Reynolds T de Zafra C Kim A et al. Overview of biopharmaceuticals and comparison with small-molecule drug development. Nonclinical dev nov biol biosimilars vaccines spec biol [Internet]. Elsevier; 2013 [cited 2022 Jun 3]. p. 3\u201333. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123948106000010","DOI":"10.1016\/B978-0-12-394810-6.00001-0"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-921-1_1"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0133-6"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.961420"},{"key":"e_1_3_4_13_1","unstructured":"SANDOZ. Leuprolide Acetate Injection [Internet]. p. 4. cited 2021 Dec 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/074728s011lbl.pdf"},{"key":"e_1_3_4_14_1","unstructured":"ELIGARD\u00ae (leuprolide acetate for injectable suspension) | tolmar [Internet]. cited 2021 Dec 7]. Available from: https:\/\/www.tolmar.com\/products\/eligard"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0499-6"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.10.008"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-019-00453-z"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040263"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00089"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-019-00449-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10965-017-1426-x"},{"key":"e_1_3_4_22_1","unstructured":"Lupron Depot (leuprolide acetate for depot suspension) [Internet]. cited 2021 Nov 10]. Available from: https:\/\/www.lupron.com"},{"key":"e_1_3_4_23_1","unstructured":"SANDOSTATIN\u00ae LAR Depot (octreotide acetate) for acromegaly and carcinoid syndrome [Internet]. cited 2021 Nov 10]. Available from: https:\/\/www.us.sandostatin.com"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.04.016"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025013"},{"key":"e_1_3_4_26_1","unstructured":"About Zoladex\u00ae | zoladex\u00ae (goserelin acetate implant) [Internet]. cited 2021 Nov 15]. Available from: https:\/\/www.zoladex.com\/what-is-zoladex"},{"key":"e_1_3_4_27_1","unstructured":"[Internet]. cited 2021 Nov 5]. Available from: https:\/\/scenesse.com"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201900818"},{"key":"e_1_3_4_29_1","unstructured":"Pipeline | Camurus [Internet]. cited 2021 Nov 8]. Available from: https:\/\/www.camurus.com\/pipeline"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano11061578"},{"key":"e_1_3_4_31_1","unstructured":"TNF-Bound colloidal gold in treating patients with advanced solid tumors - ClinicalTrials.gov [Internet]. cited 2021 Nov 9]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00356980."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2019.00001"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.10.012"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.10.015"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02074-y"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168884"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S46970"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.04.042"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.01.012"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.05.057"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b01188"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.01.023"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.36.1095"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.36.1502"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.36.2576"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00619"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0253-2"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120450"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120907"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.04.039"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(03)00366-3"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1685-3"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.06.044"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9914-2"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.03.006"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.06.017"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1943056"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/088532803038026"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585880-000000000-00000"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3640"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym10121379"},{"key":"e_1_3_4_63_1","doi-asserted-by":"crossref","unstructured":"Sequeira JAD Santos AC Serra J et al. Poly(lactic- co -glycolic acid) (PLGA) matrix implants. Nanostructures Eng Cells Tissues Organs [Internet]. Elsevier; 2018 [cited 2021 Nov 29]. p. 375\u2013402. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128136652000107","DOI":"10.1016\/B978-0-12-813665-2.00010-7"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.07.002"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0184-6"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500778"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.7.9.1483"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02741-7"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666141122211920"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.01.022"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217738150"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.112"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.05.003"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa479"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12698"},{"key":"e_1_3_4_76_1","first-page":"550","article-title":"The formulation and immunogenicity of therapeutic proteins: product quality is a key factor","volume":"13","author":"Richard J","year":"2010","unstructured":"Richard J, Prang N. The formulation and immunogenicity of therapeutic proteins: product quality is a key factor. Thomson Reuters. 2010;13:550\u2013558.","journal-title":"Thomson Reuters"},{"key":"e_1_3_4_77_1","doi-asserted-by":"crossref","unstructured":"Lee PW Pokorski JK. PLGA devices: production and applications for sustained protein delivery. 2019;38.","DOI":"10.1002\/wnan.1516"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20625"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2014.882940"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.02.025"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118505"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(98)00148-5"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.07.006"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.09.003"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1516"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2007.09.004"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1138"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24546"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.04.005"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.22336"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119441"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.11.033"},{"key":"e_1_3_4_93_1","unstructured":"Zhu G Schwendeman SP Stabilization of Proteins Encapsulated in Cylindrical Poly(lactide-co-glycolide) Implants: mechanism of Stabilization by Basic Additives.:7."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016482809810"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12040303"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.06.010"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201800220"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400666b"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.01.017"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23931"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11705-018-1729-4"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527802104.ch7"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1080\/07373937.2021.1903032"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.07.024"},{"key":"e_1_3_4_106_1","unstructured":"Immunogenicity Assessment for Therapeutic Protein Products | FDA [Internet]. cited 2021 Dec 17]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-assessment-therapeutic-protein-products"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2018.12.075"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.07.024"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.12.010"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0523-5"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086322"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159328"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00601"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.01.010"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tec.2018.0024"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2017.08.003"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-72379-2_11"},{"key":"e_1_3_4_118_1","unstructured":"Lal RA Hoffman AR. Long-acting growth hormone preparations in the treatment of children. 2019;9."},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.09.072"},{"key":"e_1_3_4_120_1","unstructured":"Polymer technologies - Innocore Pharma [Internet]. cited 2021 Nov 29]. Available from: https:\/\/www.innocorepharma.com\/nl\/Technologies\/Polymer%20technologies\/SynBiosys%C2%AE"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2014.02.012"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-017-0408-1"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0978"},{"key":"e_1_3_4_124_1","unstructured":"[Internet]. cited 2022 Apr 12]. Available from: https:\/\/www.cytimmune.com\/pipelilne"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.441"},{"key":"e_1_3_4_126_1","unstructured":"OctoPlus. PolyActiveTM A biodegradable polymer-based drug delivery system [Internet]. 2006 cited 2021 Dec 2]. Available from: http:\/\/www.afinitica.com\/arnews\/sites\/default\/files\/techdocs\/PolyActive_Nov20061%5B1%5D.pdf"},{"key":"e_1_3_4_127_1","unstructured":"Biolex Therapeutics Inc. An Open-Label 3-Panel Dose-Escalation Study to Assess the Safety and Tolerability Pharmacokinetics and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C [Internet]. clinicaltrials.gov; 2012 [cited 2021 Dec 1]. Report No.: NCT00593151. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00593151."},{"key":"e_1_3_4_128_1","unstructured":"Biolex therapeutics researchers present Locteron\u00ae U.S. Phase 2a Hepatitis C Trial Results at EASL Conference | proteins and Peptides | news Channels [Internet]. cited 2021 Dec 1]. Available from: https:\/\/pipelinereview.com\/index.php\/2009042426544\/Proteins-and-Peptides\/Biolex-Therapeutics-Researchers-Present-Locteron-U.S.-Phase-2a-Hepatitis-C-Trial-Results-at-EASL-Conference.html"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101533"},{"key":"e_1_3_4_130_1","unstructured":"Technology \u2013 bioChaperone\u00ae \u2013 ADOCIA a biotechnology company dedicated to protein delivery [Internet]. cited 2021 Nov 29]. Available from: https:\/\/www.adocia.com\/technology\/biochaperone-technology-2"},{"key":"e_1_3_4_131_1","unstructured":"Products \u2013 bioChaperone\u00ae ultra-rapid insulin \u2013 ADOCIA a biotechnology company dedicated to protein delivery [Internet]. cited 2021 Dec 1]. Available from: https:\/\/www.adocia.com\/products\/biochaperone-ultra-fast-analog-insulin"},{"key":"e_1_3_4_132_1","unstructured":"Adocia ends BioChaperone PDGF development after phase III Failure [Internet]. cited 2021 Dec 1]. Available from: https:\/\/www.genengnews.com\/news\/adocia-ends-biochaperone-pdgf-development-after-phase-iii-failure"},{"key":"e_1_3_4_133_1","first-page":"e1992","article-title":"Systemic and local drug delivery for treating diseases of the central nervous system in rodent models","author":"Serwer L","year":"2010","unstructured":"Serwer L, Hashizume R, and Ozawa T, et al. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. J Vis Exp. 2010;e1992.","journal-title":"J Vis Exp"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2010.03.001"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.159"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.12.010"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1080\/00913847.2017.1357421"},{"key":"e_1_3_4_138_1","unstructured":"Intra-tumoral ipilimumab plus intravenous nivolumab following the resection of recurrent glioblastoma - ClinicalTrials.gov [Internet]. cited 2021 Apr 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03233152"},{"key":"e_1_3_4_139_1","unstructured":"Intratumoral Tilsotolimod a TLR-9 agonist together with intratumoral ipilimumab and intravenous nivolumab in patients with advanced cancers - ClinicalTrials.gov [Internet]. cited 2021 Apr 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04270864"},{"key":"e_1_3_4_140_1","unstructured":"A trial evaluating the safety & efficacy of intra-tumoral ipilimumab in combination with intra-venous nivolumab in patients with metastatic melanoma - clinicalTrials.gov [Internet]. cited 2021 Apr 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02857569"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1456"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-019-0108-1"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0469"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy423"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001800"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181a94f01"},{"key":"e_1_3_4_147_1","doi-asserted-by":"crossref","unstructured":"Otero-Espinar FJ Fern\u00e1ndez-Ferreiro A Gonz\u00e1lez-Barcia M et al. Stimuli sensitive ocular drug delivery systems. Drug target stimuli sensitive drug deliv syst [Internet]. Elsevier; 2018 [cited 2021 Nov 26]. p. 211\u2013270. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128136898000069.","DOI":"10.1016\/B978-0-12-813689-8.00006-9"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-019-0156-6"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.05.007"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-8-5"},{"key":"e_1_3_4_152_1","first-page":"48","article-title":"Formulation Strategies based on Supercritical Fluid Technology for the Delivery of Biopharmaceuticals","volume":"26","author":"Richard J","year":"2008","unstructured":"Richard J. Formulation Strategies based on Supercritical Fluid Technology for the Delivery of Biopharmaceuticals. Chem Today. 2008;26:48\u201351.","journal-title":"Chem Today"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.14.111"},{"key":"e_1_3_4_154_1","unstructured":"Cherif-Cheikh R Delgado De Sousa A-P Lacombe F et al. Sustained release formulations comprising very low molecular weight polymers."},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2017-0024"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020542"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.12.006"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0192-9"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0156"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14729"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2022.2105318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:16:11Z","timestamp":1770372971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2022.2105318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":158,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/17425247.2022.2105318"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2022.2105318","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}